I. Biological Behaviour of Human Tumours Transplanted in Mice and the Evaluation of Therapeutic Response.- The Therapeutic Response of a Variety of Human Tumour Xenografts.- Biology of Human Ovarian Cancer Xenografts.- Representativity of Xenografts for Clinical Cancer. Tumor and Host Characteristics as Variables of Tumor Take Rate.- II. Prediction of Tumour Response for the Individual Patient by the Human Tumour Xenograft.- Comparison of Tumor Response in Nude Mice and in Patients.- III. Prediction of Antitumour Activity per Tumour Type by the Human Tumour Xenograft.- Conventional Agents in Human Ovarian Cancer Xenografts.- Activity of Conventional Drugs in Head and Neck Cancer Xenografts.- Preclinical Drug Evaluation with Human Melanoma Xenografts.- Lung Xenografts as a Predictive Screen for Antineoplastic Agents.- Chemotherapy Studies in Human Non-Small Cell Lung Cancer Xenografts Transplanted in Immune-Deprived Mice.- Establishment and Response to Chemotherapy of Human Cervical Carcinoma Xenografts.- The Usefulness of the Nude Mouse Model for Predicting the Chemosensitivity of Human Tumors. Studies in Malignant Melanoma.- IV. Preclinical Evaluation of Analogs of Known Anticancer Agents.- Screening of Analogs in Human Ovarian Cancer Xenografts.- Predictability of Clinical Response of Several Human and Murine Tumor Models to Four Anthracycline Derivatives.- V. New Drugs.- Activity of Six New Drugs in Head and Neck Cancer Xenografts.- Activity of Metallocene Complexes Against Human Tumours Heterotransplanted into Athymic Mice.- VI. Human Tumour Xenografts in the Development of Biological Response Modifiers.- The Effect of Human and Murine Interferons on Human Tumour Xenografts.- Biodistribution and Therapeutic Efficacy of a Monoclonal Antibody-Methotrexate Conjugate in Mice.- The Effect of Interferon-Alpha on the Activity of Cytotoxic Drugs in Bronchial Carcinoma Xenografts.- The Nude Mouse for the Study of Immunotoxins.- VII. Human Tumour Xenografts in Drug Screening.- Proposal for the Application of Xenografts in Screening for New Anticancer Agents and in Selecting Tumor Types for Phase II Clinical Trials.- Human Tumour Xenograft Models for Use with an In Vitro-Based, Disease-Oriented Antitumour Drug Screening Program.- VIII. Importance of Drug Resistance in Screening.- Mechanisms of Drug Resistance in Screening.- Circumvention of Inherent Resistance with Verapamil in a Human Tumour Xenograft.- IX. Proferred Papers at the E. S. O. Seminar.- Clonogenic Assay Screening Study Group (CASSG): Contribution to an EORTC Drug Screening Programme.- Polyamine Uptake by Malignant Brain Tumour Xenografts in Nude Mice.- The Activity for a Novel Niteosourea (TCNU) in Human Lung Cancer Xenografts.- Xenografts in Pharmacologically Immunosuppressed Mice as a Model to Test the Chemotherapeutic Sensitivity of Human Tumours.- New Tissue-Specific Metastasis Models in Adult Nude Mice.- Fractionated Irradiation of Human Tumor Xenografts in Athymic Nude Mice.- An Animal Model for Human Tumor Xenografts.- Xenografted Human Tumors in Preclinical Drug Design.- Growth in Nude Mice of a T-Cell Line from a Case of Acute Lymphoblastic Leukaemia: A Model for Experimental Immunotherapy of Human Neoplasia.- 5-Fluorouracil (5-FU) + Cis-diamminedichloroplatinum (DDP) Treatment of Human Colorectal Tumor Xenografts.- Inter and Intra-Tumor Variation in the Response to Chemotherapy of Human Small Cell Carcinoma of the Lung (SCCL) Grown in Nude Mice.- Human Carcinoma Cell Lines Xenografted in Athymic Mice: Biological and Antigenic Characterization of an Intra-Abdominal Model.- Squamous Cell Carcinoma Xenografts as a Model for the Study of Drug-Induced Cell Kinetic Changes in Head and Neck Cancer.